TGF-β and glomerulonephritis: Anti-inflammatory versus prosclerotic actions

Nephrology Dialysis Transplantation

Volumn 12, Issue 4, 1997, Pages 669-679

  Kitamura, M ^a   Suto T S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; KIDNEY FIBROSIS; KIDNEY INJURY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL DIVISION; CYTOKINES; EXTRACELLULAR MATRIX; FIBROSIS; GLOMERULONEPHRITIS; HUMANS; KIDNEY GLOMERULUS; MACROPHAGES; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030891040     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.4.669     Document Type: Review

References (161)

1. De Larco JE, Todaro GJ. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 1978; 75: 4001-4005
2. Roberts AB, Lamb LC, Newton DL, Sporn MB, De Larco JE, Todaro GJ. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci USA 1980; 6: 3494-3498
3. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990; 6: 597-641
4. Thompson NL, Flanders KC, Smith JM, Eliingsworth LR, Roberts AB, Sporn MB. Expression of transforming growth factor-β1 in specific cells and tissues of adult and neonatal mice. J Cell Biol 1989; 108: 661-669
5. Miller DA, Lee A, Pelton RW, Chen EY, Moses HL, Derynck R. Murine transforming growth factor-β2 cDNA sequence and expression in adult tissues and embryos. Mol Endocrinol 1989; 3: 1108-1114
6. Pelton RW, Saxena B, Jones M, Moses HL, Gold LI. Immunohistochemical localization of TGF-β1, TGF-β2 and TGF-β3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J Cell Biol 1991; 115: 1091-1095
7. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292
8. Border WA, Noble NA. Cytokines in kidney disease: the role of transforming growth factor-β. Am J Kidney Dis 1993; 22: 105-113
9. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 1990; 86: 453-462
10. Border WA, Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J Clin Invest 1992; 90: 1-7
11. Border WA, Noble NA. Transforming growth factor-beta in glomerular injury. Exp Nephrol 1994; 2: 13-17
12. Wakefield LM, Smith DM, Flanders KC, Sporn MB. Latent transforming growth factor-β from human platelets - a high molecular weight complex containing precursor sequences. J Biol Chem 1988; 263: 7646-7654
13. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J Cell Biol 1988; 106: 1659-1665
14. Massague J. TGF-β signaling: receptors, transducers and Mad proteins. Cell 1996; 85: 947-950
15. Alexandrow MG, Moses HL. Transforming growth factor-β and cell cycle regulation. Cancer Res 1995; 55: 1452-1457
16. Yamaguchi K, Shirakabe K, Shibuya H et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 1995; 270: 2008-2011
17. Shah M, Foreman DM, Ferguson MWJ. Neutralization of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous wounds reduces scarring. J Cell Sci 1995; 108: 983-1002
18. Ohta M, Greenberger JS, Anklesaria P, Bassols A, Massague J. Two forms of transforming growth factor β distinguished by multipotential progenitor cells. Nature 1987; 329: 539-541
19. MacKay K, Kondaiah P, Danielpour D, Austin III HA, Brown PD. Expression of transforming growth factor-β1 and β2 in rat glomeruli. Kidney Int 1990; 38: 1095-1100
20. Ando T, Okuda S, Tamaki K, Yoshitomi K, Fujishima M. Localization of transforming growth factor-β and latent transforming growth factor-β binding protein in rat kidney. Kidney Int 1995; 47: 733-739
21. Yamamoto T, Noble NA, Cohen AH et al. Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int 1996; 49: 461-469
22. Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int 1994; 45: 916-927
23. Kitamura M, Sütö TS, Yokoo T, Shimizu F, Fine LG. Transforming growth factor-β1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells. J Immunol 1996; 156: 2964-2971
24. Sütö TS, Fine LG, Kitamura M. Mesangial cell-derived transforming growth factor-β1 reduces macrophage adhesiveness with consequent deactivation. Kidney Int 1996; 50: 445-452
25. Lacave R, Rondeau E, Ochi S, Delarue F, Schleuning WD, Sraer J. Characterization of a plasminogen activator and its inhibitor in human mesangial cells. Kidney Int 1989; 35: 806-811
26. Sappino A-P, Huarte J, Vassalli J-D, Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 1991; 87: 962-970
27. Ding G, van Goor H, Frye J, Diamond JR. Transforming growth factor-beta expression in macrophages during hypercholesterolemic states. Am J Physiol 1994; 267: F937-F943
28. Lianos EA, Orphanos V, Cattell V, Cook T, Anagnou N. Glomerular expression and cell origin of transforming growth factor-beta 1 in anti-glomerular basement membrane disease. Am J Med Sci 1994; 307: 1-5
29. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets. J Biol Chem 1983; 258: 7155-7160
30. Roberts AB, Sporn MB. The transforming growth factor-βs. In: Sporn MB, Roberts AB (eds.). Peptide Growth Factors and Their Receptors. I. Springer, Berlin, 1990; 419-472
31. Bruijn JA, Roos A, De Geus B, De Heer E. Transforming growth factor-β and the glomerular extracellular matrix in renal pathology. J Lab Clin Med 1994; 123: 34-47
32. Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin proteinase system. Kidney Int 1992; 42: 1462-1469
33. Kagami S, Border WA, Ruoslahti E, Noble NA. Coordinated expression of β1 integrins and transforming growth factor-β-induced matrix proteins in glomerulonephritis. Lab Invest 1993; 69: 68-76
34. Kitamura M, Maruyama N, Mitarai T, Nagasawa R, Yoshida H, Sakai O. Extracellular matrix contraction by cultured mesangial cells: modulation by transforming growth factor-β and matrix components. Exp Mol Pathol 1992; 56: 132-143
35. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993; 92: 2597-2601
36. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by anti-serum against transforming growth factor β1. Nature 1990; 346: 371-374
37. Border WA, Noble NA, Yamamoto T et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992; 360: 361-364
38. Isaka Y, Brees DK, Ikegaya K et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 1996; 2: 418-423
39. Isaka Y, Akagi Y, Kaneda Y et al. Gene therapy by TGF-β-receptor-IgG Fc chimera inhibited extracellular matrix accumulation in experimental glomerulonephritis. J Am Soc Nephrol 1996; 7: 1735 (abstract)
40. Akagi Y, Isaka Y, Arai M et al. Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996; 50: 148-155
41. Sanderson N, Factor V, Nagy P et al. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995; 92: 2572-2576
42. Sporn MB, Roberts AB. A major advance in the use of growth factors to enhance wound healing. J Clin Invest 1993; 92: 2565-2566
43. Mundy GR. The effects of TGF-beta on bone. Ciba Found Symp 1991; 157: 137-143
44. Coombs LM, Pigott DA, Eydmann ME, Proctor AJ, Knowles MA. Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinoma. Br J Cancer 1993; 67: 578-584
45. Markowitz S, Wang J, Myeroff L et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-1338
46. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein (a) mice. Nature 1994; 370: 460-462
47. Grainger DJ, Kemp PR, Metcalfe JC et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med 1995; 1: 74-79
48. Lefer AM, Ma X-L, Weyrich AS, Scalia R. Mechanism of the cardioprotective effect of transforming growth factor β1 in feline myocardial ischemia and reperfusion. Proc Natl Acad Scu USA 1993; 90: 1018-1022
49. Lefer AM. Mechanisms of the protective effects of transforming growth factor-β in reperfusion injury. Biochem Pharmacol 1991; 42: 1323-1327
50. Perrella MA, Hsieh C-M, Lee W-S et al. Arrest of endotoxin-induced hypotension by transforming growth factor-β1. Proc Natl Acad Sci USA 1996; 93: 2054-2059
51. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS. Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986; 137: 3855-3860
52. Kehrl JH, Thevenin C, Rieckmann P, Fauci AS. Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from membrane form to the secreted form of Ig mRNA. J Immunol 1991; 146: 4016-4023
53. Ristow HJ. BSC-1 growth inhibitor type β transforming growth factor is a strong inhibitor of thymocyte proliferation. Proc Natl Acad Sci USA 1986; 83: 5531-5533
54. Kehrl JH, Wakefield LM, Roberts AB et al. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163: 1037-1050
55. Rook AH, Kehrl JH, Wakefield LM et al. Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136: 3916-3920
56. Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. Science 1988; 242: 97-99
57. Tsunawaki S, Sporn MB, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-β. Nature 1988; 334: 260-262
58. Wahl SM, McCartney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-β. Immunol Today 1989; 10: 258-261
59. Brandes ME, Allen JB, Ogawa Y, Wahl SM. Transforming growth factor-β1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991; 87: 1108-1113
60. Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ. Protective effect of transforming growth factor-β1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991; 88: 2918-2921
61. Pankewycz OG, Guan JX, Treveldi E. Early therapy of NOD mice with transforming growth factor β2 diminishes insulitis and reduces the incidence of diabetes. J Am Soc Nephrol 1994; 5: 761 (abstract)
62. Dang H, Geiser AG, Letterio JJ et al. SLE-like autoantibodies and Sjögren syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol 1995; 1555: 3205-3212
63. Raz E, Watanabe A, Baird SM et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci USA 1993; 90: 4523-4527
64. Qin L, Chavin KD, Ding Y et al. Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-β1. Ann Surg 1994; 220: 508-519
65. Shull MM, Ormsby I, Kier AB et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-699
66. Kulkarni AB, Huh CG, Becker D et al. Transforming growth factor-β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90: 770-774
67. Jaffer F, Saunders C, Schultz P, Throckmorton D, Weinshell E, Abboud HE. Regulation of mesangial cell growth by polypeptide mitogens. Inhibitory role of transforming growth factor beta. Am J Pathol 1989; 135; 261-269
68. Nakamura T, Miller D, Ruoslahti E, Border WA. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-β1. Kidney Int 1992; 41: 1213-1221
69. Choi ME, Ballermann BJ. Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-β receptors. J Biol Chem 1995; 270: 21144-21150
70. Kitamura M, Burton S, English J, Kawachi H, Fine LG. Transfer of a mutated gene encoding active transforming growth factor-β1 suppresses mitogenesis and IL-1 response in the glomerulus. Kidney Int 1995; 48: 1747-1757
71. Shoecklmann HO, Rupprecht HD, Zauner I, Sterzel RB. TGF-β1-induced cell cycle arrest in mesangial cells involves inhibition of cycline E-cdk2 activation and retinoblastoma protein phosphorylation. Kidney Int (in press)
72. Derynck R. TGF-β-receptor-medialed signaling. Trends Biochem Sci 1994; 19: 548-553
73. Lovett DH, Ryan JL, Sterzel RB. Stimulation of mesangial cell proliferation by macrophage interleukin-1. J Immunol 1983; 131: 2830-2836
74. Harrison DJ. Cell death in the diseased glomerulus. Histopathology 1988; 12: 679-683
75. Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N. Apoptosis in progressive crescentic glomerulonephritis. Lab Invest 1996; 74: 941-951
76. Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota Z. Apoptosis in glomerular sclerosis. Kidney Int 1996; 49: 103-111
77. Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, Savill J. Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 1994; 94; 2105-2116
78. Shimizu A, Kitamura H, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N. Apoptosis in the repair process of experimental proliferative glomerulonephritis. Kidney Int 1995; 47: 114-121
79. Mooney A, Kitamura M, Savill J. Cytokines promote glomerular myofibroblast-like mesangial cell survival in vitro by stimulus-dependent inhibition of apoptosis. J Immunol (in press)
80. Liu Z-H, Striker GE, Stetler-Stevenson M, Fukushima P, Patel A, Striker LJ. TNF-α and IL-1α induce mannose receptors and apoptosis in glomerular mesangial but not endothelial cells. Am J Physiol 1996; 270: C1595-C1601
81. Yokoo T, Kitamura M. The inflammatory cytokine IL-1β affects intrinsic cytoprotective machinery and sensitizes glomerular cells to oxidant-initiated apoptosis. J Am Soc Nephrol 1996; 7: 1726-1727 (abstract)
82. Rotello RJ, Lieberman RC, Purchio AF, Gerschenson LE. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor β1 in cultured uterine epithelial cells. Proc Natl Acad Sci USA 1991; 88: 3412-3415
83. Oberhammer FA, Pavelka M, Sharma S et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci USA 1992; 89: 5408-5412
84. Jurgensmeier JM, Schmitt CP, Viesel E, Hofler P, Bauer G. Transforming growth factor beta-treated normal fibroblasts eliminate transformed fibroblasts by induction of apoptosis. Cancer Res 1994; 54: 393-398
85. Tsukada T, Eguchi K, Migita K et al. Transforming growth factor beta 1 induces apoptotic cell death in cultured human umbilical vein endothelial cells with down-regulated expression of bcl-2. Biochem Biophys Res Commun 1995; 210: 1076-1082
86. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nature Med 1996; 2: 1132-1136
87. Trelstad RL. The Role of Extracellular Matrix in Development. Alan R. Liss, New York, 1984
88. Rupprecht HD, Schocklmann HO, Sterzel RB. Cell-matrix interactions in the glomerular mesangium. Kidney Int 1996; 49: 1575-1582
89. Kitamura M, Mitarai T, Maruyama N, Nagasawa R, Yoshida H, Sakai O. Mesangial cell behavior in a three-dimensional extracellular matrix. Kidney Int 1991; 40: 653-661
90. Yaoita E. Behavior of rat mesangial cells cultured within extracellular matrix. Lab Invest 1989; 61: 410-418
91. Marx M, Daniel TO, Kashgarian M, Madri JA. Spatial organization of the extracellular matrix modulates the expression of PDGF-receptor subunits in mesangial cells. Kidney Int 1993; 43: 1027-1041
92. 6GG elements. J Am Soc Nephrol 1996; 7: 1757 (abstract)
93. Kitamura M, Shirasawa T, Maruyama N. Gene transfer of metalloproteinase transin induces aberrant behavior of cultured mesangial cells. Kidney Int 1994; 45: 1580-1586
94. Kitamura M, Mitarai T, Nagasawa R, Maruyama N. Differentiated phenotype of glomerular mesangial cells in nodular culture. Am J Physiol 1996; 270: F614-F622
95. Roberts AB, Heine UI, Flanders KC, Sporn MB. Transforming growth factor-β: major role in the regulation of extracellular matrix. Ann NY Acad Sci 1990; 580: 225-232
96. Marti HP, Lee L, Kashgarian M, Lovett DH. Transforming growth factor-β1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am J Pathol 1994; 144: 82-94
97. Lovett DH, Johnson RJ, Marti H-P, Martin J, Davies M, Couser WG. Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am J Pathol 1992; 141: 85-98
98. Dinarello CA. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr Opin Immunol 1991; 3: 941-948
99. Sedor JR, Nakazato Y, Konieczkowski M. Interleukin-1 and the mesangial cell. Kidney Int 1992; 41: 595-599
100. Sedor JR. Cytokines and growth factors in renal injury. Semin Nephrol 1992; 12: 428-440
101. Pfeilschifter J, Schwartzenbach H. Interleukin 1 and tumor necrosis factor stimulate cGMP formation in rat renal mesangial cells. FEBS Lett 1990; 273: 185-187
102. Zoja C, Wang JM, Bettoni S et al. Interleukin-1β and tumor necrosis factor-α induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am J Pathol 1991; 138: 991-1003
103. Redini F, Mauviel A, Pronost S, Loyau G, Pujol J-P. Transforming growth factor-β exerts opposite effects from interleukin-1β on cultured rabbit articular chondrocytes through reduction of interleukin-1 receptor expression. Arthritis Rheum 1993; 36: 44-50
104. van Beuningen HM, van der Kraan PM, Arntz OJ, van der Berg WB. Protection from interleukin 1 induced destruction of articular cartilage by transforming growth factor-β: studies in anatomically intact cartilage in vitro and in vivo. Ann Rheum Dis 1993; 52: 185-191
105. Dubois CM, Ruscetti FW, Palaszynski EW, Falk LA, Oppenheim JJ, Keller JR. Transforming growth factor β is a potent inhibitor of IL-1 receptor expression: proposed mechanism of inhibition on IL-1 action. J Exp Med 1990; 172: 737-744
106. Pfeilschifter J, Vosbeck K. Transforming growth factor β2 inhibits interleukin 1β- and tumour necrosis factor α-induction of nitric oxide synthase in rat renal mesangial cells. Biochem Biophys Res Commun 1991; 175: 372-379
107. Vervoordeldonk MJ, Schalkwijk CG, Pfeilschifter J, van den Bosch H. Effects of dexamethasone and transforming growth factor-beta 2 on group II phospholipase A2 mRNA and activity levels in interleukin 1 beta- and forskolin-stimulated mesangial cells. Biochem J 1996; 315: 435-441
108. Danoff TM, Jiang HB. TGF-β1 suppresses the induction of Rantes by TNF-α. J Am Soc Nephrol 1996; 7: 1696 (abstract)
109. Nakagawa Y, Kuroda T, Narita I et al. Decorin suppresses TGF-β mRNA expression in rat anti-GBM nephritis. J Am Soc Nephrol 1994; 5: 698 (abstract)
110. Tang WW, Feng L, Vannice JL, Wilson CB. Interleukin-1 receptor antagonist ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis. J Clin Invest 1994; 93: 273-279
111. Lan HY, Nikolic-Paterson DJ, Zarama M, Vannice JL, Atkins RC. Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int 1993; 43: 479-485
112. Hooke DH, Gee DC, Atkins RC. Leukocytes analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int 1987; 31: 964-972
113. Main IW, Nikolic-Paterson DJ, Atkins RC. T cells and macrophages and their role in renal injury. Semin Nephrol 1992; 12: 395-407
114. Nathan C. Mechanisms and modulation of macrophage activation. Behring Inst Mitt 1991; 88: 200-207
115. Springer TA, Anderson DC. The importance of the Mac-1, LFA-1 glycoprotein family in monocyte and granulocyte adherence, chemotaxis, and migration into inflammatory sites: insights from an experiment of nature. Ciba Found Symp 1986; 118: 102-126
116. Newman SL, Tucci MA. Regulation of human monocyte/ macrophage function by extracellular matrix. Adherence of monocytes to collagen matrices enhances phagocytosis of opsonized bacteria by activation of complement receptors and enhancement of Fc receptor function. J Clin Invest 1990; 86: 703-714
117. Azevedo NL, de Souza W. A cytochemical study of the interaction between Tritrichomonas foetus and mouse macrophages. Parasitol Res 1992; 78: 545-552
118. Haskill S, Johnson C, Eierman D, Becker S, Warren K. Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. J Immunol 1988; 140: 1690-1694
119. Shaw RJ, Doherty DE, Ritter AG, Benedict SH, Clark RAF. Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. J Cell Biol 1990; 111: 2139-2148
120. Hughes DA, Fraser IP, Gordon S. Murine macrophage scavenger receptors: in vivo expression and function as receptor for macrophage adhesion in lymphoid and non-lymphoid organs. Eur J Immunol 1995; 25: 466-473
121. Fraser I, Hughes D, Gordon S. Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor. Nature 1993; 364: 343-346
122. Bottalico LA, Wager RE, Agellon LB, Assoian RK, Tabas I. Transforming growth factor-β1 inhibits scavenger receptor activity in THP-1 human macrophages. J Biol Chem 1991; 266: 22866-22871
123. Hogasen AK, Hestdal K, Hogasen K, Abrahamsen TG. Transforming growth factor beta modulates C3 and factor B biosynthesis and complement receptor 3 expression in cultured human monocytes. J Leuk Biol 1995; 57: 287-296
124. Kawachi H, Iwanaga T, Toyabe S, Oite T, Shimizu F. Mesangial sclerotic change with persistent proteinuria in rats after two consecutive injection of monoclonal antibody 1-22-3. Clin Exp Immunol 1992; 90: 129-134
125. Lan HY, Nikolic-Paterson DJ, Atkins RC. Trafficking of inflammatory macrophages from the kidney to draining lymph nodes during experimental glomerulonephritis. Clin Exp Immunol 1993; 92: 336-341
126. Melcion C, Lachman L, Killen PD, Morel-Maroger L, Striker GE. Mesangial cells, effect of monocyte products on production and matrix synthesis. Transplant Proc 1982; 14: 559-564
127. Espevik T, Figari IS, Shalaby MR et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J Exp Med 1987; 166: 571-576
128. Bogdan C, Paik J, Vodocotz Y, Nathan C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10. J Biol Chem 1992; 267: 23301-23308
129. Kitamura M. Identification of an inhibitor targeting macrophage production of monocyte chemoattractant protein-1 as transforming growth factor-β1. J Immunol (in press)
130. Sütö TS, Fine LG, Kitamura M. Production of matrix metalloproteinase by activated macrophages and bystander mesangial cells: identification of paracrine counter-regulatory loops via IL-1β and TGF-β1. J Am Soc Nephrol 1996; 7: 1666 (abstract)
131. Kitamura M, Sütö TS. Transfer of genetically engineered macrophages into the glomerulus. Kidney Int (in press)
132. Shah SV. Oxidant mechanisms in glomerulonephritis. Semin Nephrol 1991; 11: 320-326
133. Shah SV. The role of reactive oxygen metabolites in glomerular disease. Ann Rev Physiol 1995; 57: 245-262
134. Boyce NW, Tipping PG, Holdsworth SR. Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. Kidney Int 1989; 35: 778-782
135. Oberle GP, Niemeyer J, Thaiss F, Schoeppe W, Stahl RAK. Increased oxygen radical and eicosanoid formation in immune-mediated mesangial cell injury. Kidney Int 1992; 42: 69-74
136. Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48: 20-32
137. Cattell V, Cook HT. Nitric oxide: role in the physiology and pathology of the glomerulus. Exp Nephrol 1993; 1: 265-280
138. Shultz PJ, Raij L. Endogenously synthesized nitric oxide preα vents endotoxin-induced glomerular thrombosis. J Clin Invest 1992; 90: 1718-1725
139. Kubes P, Kanwar S, Niu X-F, Gaboury JP. Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and mast cells. FASEB J 1993; 7: 1293-1299
140. Florquin S, Amraoui Z, Dubois C, Decuyper J, Goldman M. The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice. J Exp Med 1994; 180: 1153-1158
141. Garg UC, Hassid A. Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am J Physiol 1989; 257: F60-F66
142. Weinberg JB, Granger DL, Pisetsky DS et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease. J Exp Med 1994; 179: 651-660
143. Narita I, Border WA, Ketteler M, Noble NA. Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 1995; 72: 17-24
144. Oswald IP, Gazzinelli RT, Sher A, James SL. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. J Immunol 1992; 148: 3578-3582
145. Ding A, Nathan CF, Graycar J, Derynck R, Stuehr DJ, Srimal S. Macrophage deactivating factor and transforming growth factor-β1, -β2, -β3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-γ. J Immunol 1990; 145: 940-944
146. Vodovotz Y, Bogdan C, Paik J, Xie Q-W, Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor β. J Exp Med 1993; 178: 605-613
147. Tomita N, Higaki J, Morishita R et al. Direct in vivo gene introduction into rat kidney. Biochem Biophys Res Commun 1992; 186: 129-134
148. Kitamura M, Taylor S, Unwin R, Burton S, Shimizu F, Fine LG. Gene transfer into the rat renal glomerulus via a mesangial cell vector: site-specific delivery, in situ amplification and sustained expression of an exogenous gene in vivo. J Clin Invest 1994; 94: 497-505
149. Kitamura M. Transfer of exogenous genes into the kidney. Exp Nephrol 1994; 2: 313-317
150. Kitamura M. Genetic manipulation of the kidney: round one. Exp Nephrol 1997; 5: 109-111
151. Kopp JB, Factor VM, Mozes M et al. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab Invest 1996; 74: 991-1003
152. Yamamoto T, Wilson CB. Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. Kidney Int 1987; 32: 514-525
153. Bagchus WM, Hoedermaeker PhJ, Rozing J, Bakker WW. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. Lab Invest 1986; 55: 680-687
154. Raz E, Dudler J, Lotz M et al. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 1995; 4: 286-292
155. Couser WG. Pathogenesis of glomerulonephritis. Kidney Int 1993; 42: S19-S26
156. Smith WB, Noack L, Khew-Goodall Y, Isenmann S, Vadas MA, Gamble JR. Transforming growth factor-beta 1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J Immunol 1996; 157: 360-368
157. Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. Science 1988; 242: 97-99
158. - antiport activity. Proc Natl Acad Sci USA 1985; 82: 6163-6166
159. Merwin JR, Newman W, Beall LD, Tucker A, Madri J. Vascular cells respond differentially to transforming growth factor beta 1 and beta 2 in vitro. Am J Pathol 1991; 138: 37-51
160. Vukicevic S, Kopp JB, Luyten FP, Sampath TK. Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7). Proc Natl Acad Sci USA 1996; 93: 9021-9026
161. Vikicevic S, Grgic M, Stavijenic A, Sampath TK. Recombinant human OP-1 (BMP-7) prevents rapid loss of glomerular function and improves mortality associated with chronic renal failure. J Am Soc Nephrol 1996; 7: 1867 (abstract).